You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommends Biomarin’s Vimizim for patients with rare life-limiting metabolic disorder

Elosulfase alfa – branded as Vimizin and made by BioMarin – is now the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.